Lietuvos sveikatos mokslų universitetas About Medicina Editorial Office Instructions to Authors Links Online Submission Old site

Medicina issued since 1920

Volume 50, Issue 1, 2014

Browse by category:

  • Abstracts
  • Articles
  • Clinical case reports
  • Guidelines
  • Reviews
  • Previous Issues

Never miss an issue!

Subscribe
Articles

Medicina (Kaunas) 2014; 50 (1): 8-13
DOI: 10.1016/j.medici.2014.05.001

Pepsinogen testing for evaluation of the success of Helicobacter pylori eradication at 4 weeks after completion of therapy.

Marcis Leja 1,2,3
Sanita Lapina 1,2
Inese Polaka 4
Dace Rudzite 1,2
Ilona Vilkoite 1,2
Ilva Daugule 1
Anna Belkovets 1,5
Sergey Pimanov 6
Jelena Makarenko 6
Ivars Tolmanis 3
Aivars Lejnieks 7
Viesturs Boka 1,2
Ingrida Rumba-Rozenfelde 1
Uldis Vikmanis 1
1 Faculty of Medicine, University of Latvia, Riga, Latvia
2 Riga East University Hospital, Riga, Latvia
3 Digestive Diseases Centre GASTRO, Riga, Latvia
4 Department of Modelling and Simulation, Riga Technical University, Riga, Latvia
5 Institute of Internal Medicine, Siberian Branch, Russian Academy of Medical Sciences, Novosibirsk, Russia
6 Department of Therapy No. 2, Vitebsk State Medical University, Vitebsk, Belarus
7 August Kirchenstein Institute of Microbiology and Virology, Riga Stradins University, Riga, Latvia
Keywords
Efficacy
Eradication
Gastrin-17
Helicobacter pylori
Pepsinogen

Pepsinogen levels in plasma are increased by inflammation in the gastric mucosa, including inflammation resulting from Helicobacter pylori infection. A decrease in pepsinogen II level has been suggested as a reliable marker to confirm the successful eradication of infection. The aim of our study was to evaluate the potential role of pepsinogens I and II, gastrin-17 and H. pylori antibodies in confirming successful eradication.
Altogether 42 patients (25 women, 17 men), mean age 45 years (range 23-74), were enrolled. Pepsinogens I and II, gastrin-17 and H. pylori IgG antibodies were measured in plasma samples using an ELISA test (Biohit, Oyj., Finland) before the eradication and 4 weeks after completing the treatment. The success of eradication was determined by a urea breath test.
Eradication was successful in 31 patients (74%) and unsuccessful in 11 patients (26%). Pepsinogen II decreased significantly in both the successful (P=0.029) and unsuccessful (P=0.042) eradication groups. Pepsinogen I decreased significantly in the successful (P=0.025) but not the unsuccessful (P=0.29) eradication group. The pepsinogen I/II ratio increased in the successful eradication group (P=0.0018) but not in the group in which treatment failed (P=0.12). There were no differences in gastrin-17 or H. pylori antibody values.
A decrease in pepsinogen II levels cannot be used as a reliable marker for the successful eradication of H. pylori 4 weeks after the completion of treatment. The increase in pepsinogen I/II ratio reflects differences in pepsinogen production following the eradication irrespective of improvement in atrophy.

Received 20 July 2013, accepted 11 January 2014, available online 5 June 2014.

Also in this category

Abstracts of the International Scientific Conference on Medicine organized within the frame of the 82nd International Scientific Conference of the University of Latvia Riga, Latvia

Abstracts accepted for the Scientific and Practical Conference “MODERN MEDICINE: a NEW APPROACH and RELEVANT RESEARCH” among the medical educational organizations of Kazakhstan, FSU and beyond, confined to the World Osteoporosis Day (WOD) conducted within the framework of NTP AR09563004 “Features of metabolism and the state of bone mineral density in adolescent girls with primary dysmenorrhea”

Also from this Author

Articles

Use of exploratory factor analysis to ascertain the correlation between the activities of rheumatoid arthritis and infection by human parvovirus B19.

(pages: 18-24)
Natalja Kakurina
Anda Kadisa
Aivars Lejnieks
et al.
Download

Articles

Pepsinogen testing for evaluation of the success of Helicobacter pylori eradication at 4 weeks after completion of therapy.

(pages: 8-13)
Marcis Leja
Sanita Lapina
Inese Polaka
et al.

Medicina is a peer-reviewed monthly scientific journal of Lithuanian Medical Association, Lithuanian University of Health Sciences and Vilnius University

eISSN 1648-9144

ISSN 1010-660X

2021 © Lithuanian University of Health Sciences, A. Mickevičiaus g. 9, LT 44307 Kaunas.

Tel. +370 37 327229, Faks. +370 37 220733, E-mail: medicina.editor (at) lsmuni.lt

Concept & code – BÜRO